Skip to main content

Search Results

Displaying: 11 - 20 of 25 Results

Small molecule inhibitors of Zika, dengue and other flaviviruses

Currently, broadly-protective antivirals targeting flaviviruses such as Zika, Dengue and West Nile viruses, are not available. Researchers in the laboratory of Dr. Priscilla Yang have identified a group of small molecules, including a prototype…

Investigators

  • Priscilla Yang

Targeting spiral ganglion neurons for treatment of hearing loss

Hearing loss makes interactions with the world challenging for over 30 million people in the United States. While cochlear implants and hearing aid devices can ameliorate hearing loss, they often fail to restore the function of spiral ganglion…

Investigators

  • Lisa Goodrich

Potent OGT inhibitors for the treatment of cancer and diabetic complications

First-in-class and potent OGT inhibitors The Walker group has developed novel high throughput assays (HTS) and screened 200,000 compounds at the Institute for Chemistry and Cell Biology (ICCB) at Harvard Medical School, and identified several…

Investigators

  • Suzanne Walker Kahne
  • Michael Lazarus
  • Benjamin Gross

Small-molecule macrocycles: Potent and selective Src kinase inhibitors

Macrocyclic compounds have unique properties that allow them to cover regions of chemical space not addressed by other small-molecule structural classes. By performing an in vitro selection screen of a broad untargeted DNA-encoded library of 13,824…

Investigators

  • David Liu
  • Ralph Kleiner

Targocil: Novel antibiotics against Methicillin-resistant Staphylococcus aureus (MRSA)

• Novel antibiotic against MRSA with sub-micromolar MIC • Potent small molecule inhibitor of wall teichoic acid (WTA) biosynthesis--an unexploited antibiotic target in Gram-positive bacteria • Tested in murine model of endophthalmitis, and MSSA and…

Investigators

  • Suzanne Walker Kahne
  • Timothy Meredith
  • Jonathan Swoboda
  • Kyungae Lee
  • Jennifer Campbell

Methods and compounds for the treatments of spinal muscular atrophy and ALS

Scientists in the Rubin laboratory have carried out an image-based screen of pharmacologically active small molecules to find compounds that increase SMN in patient fibroblasts. They have discovered more than 150 active compounds that fell into…

Investigators

  • Lee Rubin
  • Nina Makhortova
  • Yin Yang
  • Monica Bennett
  • Amy Sinor-Anderson

Trioxacarcins and analogs: DNA-modifying compounds with potent anti-proliferative effects

The trioxacarcins are a new class of DNA-modifying natural products with potent antiproliferative effects (with subnanmolar IC70 values against lung, mammary, and CNS cancer cell lines). Trioxacarcin A, B, and C were first discovered and isolated…

Investigators

  • Andrew Myers
  • Jakub Svenda
  • Nicholas Hill
  • Robert Yu
  • Daniel Smaltz
  • Thomas Magauer

Small molecule inhibitors of Ebola virus entry

Background: Human cells that are susceptible to infection by pathogenic viruses express surface membrane proteins that mediate attachment and membrane fusion activity of virus glycoproteins. There are strong structural and functional similarities…

Investigators

  • Dennis Kasper
  • Kyungae Lee
  • Tao Ren
  • James Cunningham
  • Kartik Chandran

Synthesis of compounds with peptide characteristics

Although peptides have shown some promise in clinical trials as therapeutic agents, its success has largely been limited by several factors, including rapid degradation by peptidases, poor cell permeability, and a lack of binding specificity…

Investigators

  • Gregory Verdine
  • Milan Chytil
  • Mary Didiuk
  • Tiffany Gierasch

Inhibitors of protein-processivity factor

Harvard investigators have discovered that Pol interacts with a processivity factor at a site that is distinct from sites of normal interaction between known Pol family members and other cellular factors. Unlike most protein-protein interactions,…

Investigators

  • Donald Coen
  • James Hogle
  • Harmon Zuccola
  • Kristie Bridges
  • Carl Elkin
  • Scott Lokey

Page 2 of 3